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ABSTRAK 
Pengenalan 
Tumor Keluarga Ewing (EFT) merupakan tumor yang sangat malignan dan aggresif. Ia 
adalah tumor yang sangat jarang berlaku terutamanya di negara Asia jika dibandingkan 
dengan negara-negara barat. Sejak tiga dekad yang lalu, prognosis pesakit EFT telah 
berkembang dengan begitu pesat seperti yang telah dibuktikan dalam beberapa kajian 
klinikal, terutamanya disebabkan oleh perkembangan dalam rawatan kemoterapi. Di 
negara kita, tidak banyak data mengenai kadar jangka hayat dan keputusan akhir kanak-
kanak EFT. Sehingga sekarang, belum ada kajian sebegini yang diterbitkan dari Hospital 
USM. 
 
Objektif 
Objektif kajian ini adalah untuk menilai kadar jangka hayat menyeluruh (OS) dan jangka 
hayat tanpa sebarang kejadian (EFS) di kalangan kanak-kanak yang menghidap Tumor 
Keluarga Ewing( EFT). Kami juga ingin mengkaji ciri-ciri demografik dan mengenalpasti 
faktor-faktor prognostik yang mempengaruhi EFS dan OS di kalangan kanak-kanak EFT 
yang dirawat di Hospital USM. 
 
 
  
 
Kaedah Kajian 
Kajian ini adalah kajian secara retrospektif melibatkan kanak-kanak yang berumur 0-18 
tahun yang didiagnosa sebagai EFT. Kanak-kanak dikenal pasti melalui data pendaftaran di 
Unit Onkologi dan Unit Rekod Hospital USM. Pesakit yang meninggal, hilang  atau tidak 
dapat dihubungi, surat dihantar ke Jabatan Pendaftaran Negeri untuk mendapatkan 
maklumat mengenai status akhir. Kaitan di antara data demografik dan faktor prognostik 
kepada  kadar jangka hayat/ status akhir pesakit di analisis dengan Cox Regression. 
Lengkungan kadar jangka hayat dianalisa dengan menggunakan kaedah Kaplan Miere dan 
dibandingkan dengan test Log Rank. 
 
Keputusan 
Terdapat seramai 51 orang kanak-kanak yang dikenal pasti mengidap penyakit Tumor 
Keluarga Ewing (EFT) Hospital USM. Bagaimanapun hanya 29 kanak-kanak di masukkan 
ke dalam kajian kami setelah memenuhi kriteria kemasukan. 
Purata jangkamasa temujanji adalah 21 bulan. Kadar jangka hayat menyeluruh(OS) untuk 
1, 2, 3 dan 5 tahun adalah 62.1%, 44.8%, 30.2% dan 21.6% masing-masing. Kadar jangka 
hayat tanpa kejadian(EFS) untuk 1, 2, 3 dan 5 tahun adalah masing-masing 41.9%, 26.7%, 
17.8% dan 0%. 
  
 
Analisa Multivariate Cox Regression menunjukkan bahawa faktor pembedahan (p=0.030) 
dan faktor komplikasi (p=0.045), merupakan faktor prognostik yang signifikan terhadap 
kadar jangka hayat di kalangan EFT.  
 
Kesimpulan 
Kadar jangka hayat dikalangan masyarakat kita adalah setanding dengan negara-negara 
membangun yang lain. Walaubagaimanapun, kita masih jauh ketinggalan jika 
dibandingkan dengan negara-negara maju disebabkan kadar jangka hayat kita cuma 
menghampiri separuh daripada kadar jangka hayat mereka. Kami dapat mengenal pasti 
faktor pembedahan dan komplikasi merupakan faktor prognostik yang mempengaruhi 
kepada kadar peluang hidup pesakit EFT di kalangan pesakit kami. 
 
 
 
 
 
 
 
 
 
 
 
  
 
ABSTRACT 
Introduction 
Ewing Family Tumor (EFT) is a very malignant and aggressive tumor. It was very rare 
tumor especially in Asia compare to western countries.  During the past three decades, the 
prognosis of patient with EFT had improves considerably as shown in several clinical 
trials, mainly because of improved chemotherapy regimes. In our country, there is lack of 
reports in the treatment outcome and survival of children with EFT. There is no published 
study predicting the treatment outcome in Hospital USM at present. 
Objectives 
The objectives of this study were to evaluate the Overall Survival (OS) and Event Free 
Survival (EFS) rate of patients who were diagnosed with EFT. We want to evaluate the 
demographic data and identify the possible predictive factors that determine the EFS and 
OS rate of those children with EFT and treated in Hospital USM. 
Methodology 
This is a retrospective record review of children aged 0-18 years with EFT. Children were 
identified from registration data in Oncology Unit and medical records from Record Office 
HUSM. In case of uncontactable or deceased patients, a letter was sent to State Registry to 
obtain the end result/outcome of the patients. The associations of demographic and clinical 
factors with patients outcome were determined by Cox regression. Survival curves were 
estimated by the Kaplan-Meier method and compared by the Log-rank test.  
  
 
Results 
There were 51 patients identified from the registration but then only 29 children were 
enrolled in this study, which full filled all the inclusion criteria. 
The mean duration follow up was 21 months. The OS rate at 1, 2, 3 and 5 years were 
62.1%, 44.8%, 30.2% and 21.6% respectively. The EFS rate at 1, 2, 3 and 5 years were 
41.9%, 26.7%, 17.8% and 0% respectively. 
Multivariate Cox regression analysis showed that presence of surgical intervention 
(p=0.030) and major complications (p=0.045) were significant prognostic factors to the 
survival of EFT in this study. 
Conclusion  
Survival rate among our patients was comparable to other developing countries. However 
we are far away if compared to developed countries as the survival rate only achieved 
almost half from their survival rate. We are able to identify two significant independent 
prognostic factors to the survival for EFT in our patients which were surgical intervention 
and presence of major complications. 
 
 
 
 
 
  
 
CHAPTER ONE 
INTRODUCTION 
 
1.1 BACKGROUND 
Hospital Universiti Sains Malaysia (HUSM) is the only tertiary centre for Paediatric 
Oncology in the East Coast of Penisular Malaysia, and is the referral centre for the 
childhood malignancies for the state of Kelantan, Terengganu and Pahang. The Paediatric 
Oncology Unit Hospital USM officially started in 1989. It is 23 bedded ward specifically 
designed for the treatment of children with oncological conditions. Most of the children are 
treated for haematologicaly malignancies which include acute lymphoblastic leukaemia 
(ALL), acute myeloid leukaemia (AML), lymphoma and multiple solid tumor as well as  
for bone tumor such as Osteosarcoma and Ewing Family Tumor. In Malaysia, only a few 
studies have been published on the outcome of Ewing Family Tumor (Lee A.C et al.2006).  
 
1.2 EPIDEMIOLOGY AND INCIDENCE 
Ewing Family tumor (EFT), are malignant small, round, blue cell tumors. In the past, 
Ewing’s sarcoma (ES) was first described by James Ewing in 1921 as a "diffuse 
endothelioma of bone" (Ewing et al. 1921). They have also been identified as Ewing 
Sarcoma of soft tissue (extraosseous). In 1979, Askin et al., had described Askin tumor as 
part of EFT. In 1984, Jaffe et al., described PNET (Primitive Neuroectodermal  Tumor) in 
Ewing Sarcoma. All together, they are classified as EFT as they share the same 
  
 
histological, immunohistochemical and cytogenetic characteristics. It is the second most 
frequent primary bone tumor after osteosarcoma about 34% and 56% of the malignant 
bone tumors respectively. (National Cancer Institute, 2013).  
The incidence varies among different racial group and it’s much lower in the black 
population and in Eastern and South Eastern Asians. The incidence varies with age. In 
United States, Ewing Sarcoma is the most common in the second decade of life. The rate is 
0.3 cases per million in children under 3 years of age and as high as 4.6 cases per million 
in adolescent age 15-19 years.  It is a disease affecting children and young adults with a 
peak incidence at age 15 years. Cases are very rarely occur among African or Asian 
population.  
Internationally the annual incidence rate is less than 2 cases per million children. The 
incidence of Ewing sarcoma has remained unchanged for the past 30 years. The incidence 
for all ages is one case per 1 million people in the United States. In patients between age 
10 to 19 years, the incidence is between 9 and 10 cases per 1 million people. The same 
analysis suggests that the incidence of Ewing sarcoma in the United States is nine times 
greater in whites than in African Americans, with an intermediate incidence in Asians. 
Based on SEER, (Surveillance, Epidemiology and End Result) program series in the USA 
between 1973- 1985,  this tumor rarely occur in black patients as only 3 black patients out 
of 650 cases of Ewing Sarcoma. (Ewing J et al.1972, Kowalewski A.A et al.2011). 
It is more common in males compared to females with the ratio of 1.3 to 1.5: 1. Even 
though it’s more common in children younger than 20 years old compared to elderly, it 
  
 
tends to affect patients age more than 20 years old for the extraosseous subtype of EFT 
(Iwamoto Y, et al.2007). 
1.3 ETIOLOGY 
The exact etiology of Ewing Family Tumors is not fully understood. Some genes control 
when our cells grow, divide into new cells and die. Oncogene is the gene that helps cells to 
grow and divide.  In the other way, tumor suppressor gene is a gene that controls cells 
division or make cells die. Cancers can happen by changes in the cell’s DNA that turn on 
oncogene or turn off tumor suppressor gene. Researchers have found chromosome changes 
that lead to Ewing tumors, but these changes are not inherited. They develop in a single 
cell after a child is born. Nearly all Ewing tumor cells have changes that involve the EWS 
gene, which is found on chromosome 22. In most cases, there is translocation between 
chromosome 22 and 11. Occasionally, the translocation occurs between chromosome 22 
and 21 and rarely between 22 and another chromosomes. The translocation causes the EWS 
gene to be activated and leads to overgrowth of the cells and development of this cancer, 
but the exact way that make the genes change is not yet clear. There are no known 
lifestyle-related or environmental that can cause Ewing tumors, therefore nothing can be 
done to prevent it from happening. The only known risk factors for Ewing tumors are age, 
gender, and race/ethnicity which can’t be changed (American Cancer Society, 2016). 
 
1.4 CLINICAL FEATURES 
Ewing family tumor primarily occurs in the bone. The most common sites for Ewing 
Family Tumor are at the trunk and long bones. In truncal skeleton, the pelvis bone 
  
 
predominates, followed by scapula, vertebral bones, ribs and clavicle. Among the long 
bones involved, the most common site is the femur and followed by humerus, tibia and 
radius/ulna. It has high tendencies to metastasize especially to the lungs, bone and bone 
marrow, while metastases to the lymph nodes are rare. The progression of the tumor is 
quite rapid to form large tumors within a few weeks. The commonest and earliest 
symptoms are pain followed by swelling. The pain can be intermittent and mild but 
progresses rapidly to very intense pain that requires analgesics. If the site of tumor is 
pelvic, it was associated with paraesthesia and limping gait. Other symptoms are non-
specific such as fever, anemia, increased ESR, leukocytosis and an increase in Lactate 
Dehydrogenase (LDH) level (Iwamoto Y, et al. 2007).  
 
1.5 DIAGNOSIS 
The definitive diagnostic test is biopsy. It can be performed either by fine needle or core 
biopsy but preferably by incisional biopsy for an adequate sampling. Open biopsy is the 
best way to avoid violation of tissue flap planes and neovascular structure. Histologically, 
it composed of small round cells with high nuclear to cytoplasmic ratios that are arrayed in 
sheet. The cytoplasma is scanty, pale, vacoulated and characterized by faded boundaries. 
To differentiate EFT with other small round cell tumors are by cytogenetic and 
immunohistochemical studies, evidence that show translocation of t(11:22)(q24:q12) 
which is present in more than 85% of cases. Less occur, translocation involving EWS locus 
on chromosome 22 t(21:22)(q22:q12) and t(7;22)(p22;q12). In addition, it often PAS 
(Periodic Acid Schif) positive, (owing to intracellular glycogen) distinguished it from 
  
 
lymphoma which is PAS- negative. Some of differentiated Ewing Sarcoma may exhibit 
neural differentiation; called as PNET. In 1979, Askin et al. described a small round cell 
tumor of thoracopulmonary region (Askin Tumor) that has different pathogenesis than 
Ewing Sarcoma/PNET but recent studies failed to demonstrate any significant differences 
in the outcomes. Recent studies revealed that pathognomonic translocation between the 
EWS gene on chromosome 22 and an ETS-type gene, most commonly Fli1 gene on 
chromosome 11 in more than 95% of Ewing Sarcoma, PNETs and Askin's tumor. 
Therefore, these lesions are grouped as the same entity called the Ewing's Family Tumor 
(EFT) (Iwamoto Y, et al.2007). 
Other diagnostic tools that may help in term of diagnosis are imaging. Plain radiograph 
may exhibit periosteal reaction. It may present in any kind of bone tumor. Typically in 
Ewing Sarcoma, it appears ill defined, permeative or focally moth eaten, destructive 
intramedullary lesions in compared to sunburst type of periosteal reaction that found in 
osteosarcoma. The most precise imaging to see the local extent or degree of expansion is 
MRI. It helps for staging, surgical planning and to assess response to neoadjuvant 
chemotherapy or radiotherapy. In this study, the definitive diagnostic tools used were 
biopsy and HPE followed by serial’s imaging either Ct scan or MRI to look for staging as 
well as to see respond towards the treatment. Bone scan also values in terms of to assess 
skip bone metastases. BMA (Bone Marrow Aspiration) also offered to see the extension 
into bone marrow (Iwamoto Y, et al.2007). 
 
 
  
 
1.6 STAGING 
The systems used for staging for both benign and malignant muskuloskeletal tumors are 
created by Ennecking, WF et al.1986. The systems are based on the histological grade of 
the tumor, local extend and the presence or absence of metastasis. It helps to guide surgical 
and adjuvant therapy. The stage of a Ewing tumor is one of the most important factors 
determining prognosis and in choosing the treatment. Many oncologist stage malignant 
bone tumor including Ewing Tumor that start in the bone according to AJCC (American 
Joint Committee on Cancer) systems, which is similar to Enneking's system. Extraosseous 
Ewing Tumor (Ewing Tumor that don't start in bone) are stage differently like other soft 
tissues sarcoma (American Joint Committee on Cancer Bone, 2010, American Cancer 
Society, 2016). 
 
1.7 PROGNOSTIC FACTORS 
The most unfavorable prognostic factor is the presence of distant metastasis at diagnosis. 
When the cancer had spread at the time of diagnosis, the 5 year survival rate is about 15%- 
30% compared with localized tumor which is around 70%. The prognosis is even worse in 
patients with bone marrow metastasis at the time of diagnosis (5-year Survival rate less 
than 20%) than those with isolated pulmonary metastasis (5-year Survival rate: 30%). In 
other words, the survival rate is slightly better if the cancer has only spread to the lungs as 
opposed to having reached other organs, (American Cancer Society, 2016). Previous 
studies have analyzed prognostic factors such as metastasis disease, age, the tumor size and 
the pelvic location are the poor prognostic factors (Bacci et al.,2000, Catterill et al.,2000, 
  
 
Obata et al.,2007, Rodriguez-Gallindo et al.,2003) . Other unfavorable diagnosis includes 
larger size of tumor (> 200ml/8cm) and the site of tumor which is more central lesions as 
in the pelvis or spine in comparing to the other site such as on arms or legs. The age more 
than 10 years and poor response to chemotherapy also a poor prognostic factors, 
(American Cancer Society, 2016). 
The histological grade has no prognostic significance because all Ewing sarcomas are 
considered high grade. Blood parameters such as elevated LDH, ESR, Total white and 
Anaemia indicates more extensive disease and poorer prognosis, (American Cancer 
Society, 2016). 
Study done by Rodrıguez-Galindo et al.2007, revealed that older age, pelvic primary 
tumor, large tumors and metastatic disease were associated with worse outcome. However, 
only stage of disease and tumor size retained significance on a multivariate analysis. 
The most important prognostic factors for patients with localized disease were the local 
extension and for patients with metastatic disease, the only prognostic indicator was the 
pattern of metastasis. 
 
1.8 SURVIVAL 
There are no single criteria for definition of Overall survival (OS) and Event Free survival 
(EFS). OS is defined as the time from the diagnosis until death from any causes or until 
last follow up. EFS is defined as the interval between the date of diagnosis and the earliest 
  
 
occurrence of the following events: induction failure, relapse, death from any cause, last 
contact and development of a second malignancy. (NCI Dictionary of Cancer Terms) 
In this study, EFS was considered as the time from diagnosis to the date of any event or to 
the date when patients were confirmed to be well, or at the date of census, whichever 
occurred first. The events were considered as relapsed, defaultation, death or any major 
complications. 
OS was considered as the time from diagnosis to the date of death or at the date of census 
or last follow up. 
The 5-year survival rate refers to the percentage of patients who live at least 5 years after 
their cancer is diagnosed.  In developed countries, the 5 year relative survival for children 
with bone cancer improved from 49% in the period 1975-1984 to 63% in the period 1985-
1994 for both Osteosarcoma and Ewing sarcoma. The survival rate for osteosarcoma was 
higher than those for Ewing’s Sarcoma, (National Cancer Institute, 2013). During the past 
3 decades, the prognosis of patients of EFT has improves considerably as shown in several 
clinical trials, mainly because of improved chemotherapy regimens, (Burgert et al.,1990,  
Grier et al.,2003, Jurgens et al.,1998, Nesbit et al.,1990, Paulussen et al.,2001). 
 
1.9 TREATMENT 
Treatments of Ewing Family Tumor include neoadjuvant therapy, surgical treatment and 
chemotherapy to treat distant metastasis regardless of initial staging. Before the use of 
multi- agent chemotherapy, the long term survival was less than 10% which improved 
  
 
trendenmously to up to 70% after introduction of chemotherapy. Current anti- cancer drugs 
proven to be effective are doxorubicin(DXR), Vincristine(VCR), 
Cyclophosphamide(CPM), Actinomycin-D(ACT), Ifosfamide(IFM) and Etoposide(VP16), 
(Iwamoto Y et al.2007). 
In 1962, Pinkel et al., reported first using cyclophosphamide in solid tumor including EFT 
and showed regression of pulmonary metastasis and pleural effusion. In 1968, Hustu et al. 
reported using the combination of cyclophosphamide, VCR and radiotherapy resulted in 
sustained respond in 5 patients with Ewing's sarcoma. This is the starting of the modern 
multimodality in the treatment of Ewing Sarcoma. 
The multi agent treatments evolved further as in 1974, Rosen et al used the combination of 
4- drugs regime consist of VACD regime, (VCR, ACT, CPM and DXR) plus radiotherapy. 
This combination resulted in improved long term survival of 12 patients with Ewing 
sarcoma. Long term follow up of the IESS-1 study (Intergrouped Ewing's Sarcoma Study) 
had demonstrates the superiority of VACD regime (EFS: 60%) compare to 3 drugs regime 
(VAC Regime-EFS 24%).  In Europe, the effect of VACD four drugs regimen was also 
investigated in CESS-81(Cooperative Ewing's Sarcoma Study), revealed that 5-year free 
survival of non- metastasis Ewing sarcoma was 55%. In CESS-86 study, Ifosphamide 
(IFM) was added in VAC regime in the treatment of large tumor instead of DXR and VAC 
regime for a smaller tumor size. The 10-year survival rate was 52% in IFM group 
compared to 51% in DXR group suggesting the usefulness of VAC plus IFM as well as 
VAC plus DXR in the treatment of Ewing Sarcoma, (Iwamoto et al.,2007). 
  
 
Local treatments have a role in the management of EFT which included surgical treatment 
as well as irradiation but it remains controversial. Previous reports has demonstrate 
reduction rate of recurrence with wide resection up to less than 10%  for local control to 
those tumor which surgery is applicable and it should be made on an individual basis. 
Ewing sarcomas are sensitive to both chemotherapy and irradiation. The standard 
treatments for resectable tumor, begin with neoadjuvant chemotherapy, followed by limb-
salvage and post adjuvant chemotherapy. Formerly amputation was the only surgical 
method for local control. Currently limb salvages procedures include local resection and 
reconstruction had been replaced. 
 
1.10 MANAGEMENT IN HUSM 
In Hospital USM, paediatric oncology ward (6 Utara) in collaboration with 2 Selatan (adult 
oncology ward) and Orthopaedic ward (4 Selatan) are the team that involved in the  
management of oncology cases including EFT patients. Ward 6 Utara managed younger 
age patients up to 12 years old while patients above 12 years were managed by oncology 
adult in terms of chemotherapy and radiotherapy. Resectable tumors were referred to 
Orthopaedic surgeons for excision. 
All children who were suspected to have bone tumor based on the initial imaging either CT 
scan or MRI were proceed by gold standard diagnostic tool which were biopsy and HPE to 
confirm the diagnosis. Prior to chemotherapy, most of the children were referred for central 
line, either chemoport or Hickman catheter under general anaesthesia for prolonged 
chemotherapy medications usage and regular blood taking for monitoring the disease 
  
 
progression and complication. Bone marrow aspiration (BMA) was done at the time of 
diagnosis to look for metastases to bone marrow. Imaging with CT scan or MRI was done 
to stage the disease and predict the prognosis for the patients. 
Any patients with resectable tumor were started on neoadjuvant chemotherapy followed by 
surgical resection and then post adjuvant chemotherapy.  Then, the patients were 
undergone serials imaging consist of MRI/CT scan thorax as well as bone scan to stage the 
disease, assess the respond to the treatments, looks for recurrence and site of metastasis. 
In 6 Utara, the common chemotherapy protocol regime that had been used for the past 10 
years in the management of Ewing Family Tumor includes Euro Ewing 99 protocol and 
PNET protocol. 
While in 2S (adult oncology unit), the protocol that had been used was CAV/IE 
(Cylophosphamide, Actinomycin, Vincristine/ Ifosphamide, Etoposide) regime.  
Others chemotherapy regime that had been used included Modified PNET protocol and 
MSK protocol. 
Those who showed poor respond to the current treatments were offered for second line 
chemotherapy which was ICE protocol. To those who were at the end stage with 
overwhelming metastasis were counseled and offered for palliative care. 
Others treatments included supportive care especially during chemotherapy.  For children 
that developed severe neutropenia will be given neutropenic regime and treat infections 
with antibiotic if they developed infection/sepsis as a consequences of severe neutropenia. 
  
 
Supportive blood transfusion would be given if they developed anaemia especially when 
patients undergone certain procedure or while on chemotherapy. 
The patients who were having sepsis as consequences of severe neutopenia were 
commenced empirical broad spectrum antibiotic while awaiting culture and sensitivity and 
the choices were according to our local sensitivity or resistant pattern data from 
microbiology lab. Then it was change accordingly to the sensitivity based on the blood 
culture result. Antifungal was added if indicated. Others supportive measures such as 
inotropic support, mechanical ventilator, total parenteral nutrition were also available. 
Patients who economically compromised were referred to social welfare for financial 
support. 
 
1.11 FOLLOW UP 
All patients were followed up from time to time at paediatric clinic as well as orthopaedic 
clinic, Hospital USM. They were seen more frequently in the first year. If they were doing 
well, the follow up is every 6 months until adulthood. During follow up, assessment was 
towards looking for remission status, any recurrence or any secondary complication that 
might arise. It’s included thorough physical examination, blood investigation including 
infectious screening as well as serial imaging such as CT scan/MRI.
 
 
 
  
 
CHAPTER TWO 
OBJECTIVES AND HYPOTHESIS 
 
2.1 Objectives 
General objectives 
To determine the survival rate and prognostic factors of Ewing Family Tumor (EFT) 
children receiving treatment in Hospital USM from 1st January 2002 to 31st  December 
2012. 
 
Specific objectives: 
i. To describe the demographic and clinical characteristic of EFT children in 
Hospital USM. 
ii. To determine Overall and Event Free Survival rate of Ewing Family Tumor 
(EFT) in Hospital USM. 
iii. To describe the prognostic factors for Overall survival in EFT children 
treated in Hospital USM. 
  
2.2 Hypothesis 
1) The Overall and EFS of EFT children treated in Hospital USM is comparable to 
other developing countries. 
  
 
2) The prognostic factors for survival in children with EFT in Hospital USM are age 
at diagnosis, gender, non-pelvic tumor, disease profile, status of metastasis at 
diagnosis, the size of the tumor, surgical intervention, lung metastasis at diagnosis, 
skip bone metastasis, chemotherapy regime and major complications.  
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CHAPTER THREE 
 
METHODOLOGY 
 
3.1 Study area and patients 
 
This study was conducted in Hospital Universiti Sains Malaysia (USM), Kubang 
Kerian Kelantan.  Paediatric Oncology Unit Hospital USM officially functioned in 
1989. It is the only tertiary centre for Paediatric Oncology in East Coast of Penisular 
Malaysia. The ward involved included ward 6 Utara (Paediatric Oncology) for children 
age 12 years and below. Ward 6 Utara consists of 23 beds mainly for oncology patients. 
While for patients above 12 years old, they were placed in adult oncology ward at 2 
Selatan. Since this study involved children age up to 18 years old, both 6 Utara and 2 
Selatan ward were involved.  
 
All children who were diagnosed to have Ewing Family Tumor (EFT) between 1st 
January 2002 - 31st December 2012 at Hospital USM with additional follow up within 
12 months were included in the study. Age between 0-18 years old at diagnosis and the 
diagnosis of EFT based on Histopathology Examination (HPE) findings that fulfilled 
the criteria of ICD10 –C41.9 for Ewing Family Tumor. Children who were unable to 
trace outcome, transferred to another hospital for continuation of treatment, as well as 
referred from other hospital for continuation of chemotherapy and those with missing 
data were excluded. 
Most of the children were from Kelantan, Pahang, Terengganu and Kedah. Some of 
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them were from other parts of states in Malaysia such as Johor and Kuala Lumpur. In 
between the chemotherapy, some of them received supportive treatment in the hospital 
nearby their hometown. 
 
3.2 Treatment protocols 
Children with EFT who were diagnosed from 2002-2012, were treated with Euro 
Ewing 99 Protocol for paediatric oncology unit in 6 Utara, while in 2 Selatan they were 
treated with CAV/IE protocol. Some of the patients used PNET protocol or Memorial 
Sloan Kettering (MSK) protocol. While for salvage and palliative chemotherapy, ICE 
protocol was used as chemotherapy regime. 
 
 
3.3 Study Design 
This study was a retrospective record review study. The name and registration numbers 
were obtained from registration data at paediatric oncology unit, orthopedic ward and 
record office Hospital USM. Code number was given to each patient with a separate list 
of name. Registered number were recorded in separate list and kept by researcher. Data 
were entered using code number. Total of 51 cases were available from the registration 
record but only 46 case notes were traceable. Out of 51, 20 of them were excluded. 15 
of them due to final diagnosis not full filled the criteria of HPE diagnosis of EFT and 5 
of them due to missing folder. One patient was started chemotherapy at other hospital 
and continued chemotherapy at our hospital. One of them was diagnosed earlier than 
study period. Total of 29 patients were enrolled in this study. All the traceable case 
notes were reviewed and the data were collected on a standardized case recording form 
(Appendix A).  
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The status of metastasis/ localised at diagnosis was taken based on the first staging 
imaging done after confirmation of diagnosis by biopsy and HPE. Skip bone metastasis 
was identified by first bone scan done. The size of tumor was estimated by CT 
scan/MRI done at diagnosis and the largest diameter was used. The chemotherapy 
regime data taken in this study were the first chemotherapy given to the patients. 
 
 
3.4 Consent and ethical approval 
All parents were contacted via phone or approached during their regular follow up in 
oncology clinic but most of them were contacted via phone. A waiver of consent for 
parents whose children already passed away or not contactable (after attempted to 
contact them) was approved by USM Research and Ethical Committee (Appendix D). 
Some of them were un-contactable or deceased. Therefore a letter was sent to State 
Registry. The status and the cause of death were obtained from the information given 
by State Registry, (Appendix E). 
 
3.5 Sample size 
Sample size was calculated using Power and sample size calculation software (version 
3.0, January 2009). Sample size calculated, with type 1 error of 0.05 and power (1-B) 
of 0.8, M1 were estimated median survival time based on previous study by Kai et 
al.,2012. With HR 2.5, accrual time: 120 months, additional follow up: 12 months with 
m1 of 19 months, a sample size with 10% drops, 52 cases is required. 
While the other study by Kutlut et al.2004, HR: 3, accrual time 120 months, additional 
follow up 12 months, m1 of 20 months, a sample size with 10% drops, 93 cases are 
required. However because of study limitation only 51 patient’s record were identified 
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during the time of study, there was no sampling method applied. All 51 cases were 
enrolled in the study. 
 
 
3.6 Outcomes Measures 
The outcomes were the EFS and OS. On top of that the prognostic factors and the 
demographic data which affected the OS and EFS were identified. OS was calculated 
from the time of diagnosis to death or till the last contact or date of census. EFS was 
measured from time of diagnosis to the date of any event, well/cure or at date of 
census, which ever occurred first. Events were considered as defaultation, death, major 
complications (neurology complications, cardiac complications, neutropenia sepsis, 
bleeding complication, secondary malignancy, treatment complications) or relapsed. 
 
 
3.7 Statistical Analysis 
The statistical analysis was performed using software SPSS version 19. Descriptive 
data was analysed. The numerical data was checked for normal distribution by using 
histiogram, skewness, kurtosis, and boxplot diagram. As it was normally distributed, 
the result were expressed in mean (SD). The rest of the data were expressed in number 
and percentage (n, %). 
Event Free Survival, Overall survival and median survival rate were described using 
Kaplan Meier method. Log rank test was used to compare the survival curves of the 
subgroups.  
Univariate Cox proportional hazard model was used to explore predictors. Several 
variables were examined as potential predictors for OS. These variables included 
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gender, age at diagnosis, size of tumor (cm), pelvic vs non-pelvic site of tumor, lung 
metastasis, skip bone metastasis, disease profile, chemotherapy regime, surgical 
intervention and complications. The factors with p value less than 0.25 were included 
in the multivariate Cox proportional hazard. Those variables with more than 2 group to 
compare were used multiple comparison with bonferoni corrected p value. P value < 
0.05 was considered as significant. The variables in the final model were examined for 
interaction and assumption. 
 
3.8 Definitions 
Remission: absence of the disease clinically and radiologically. 
Defaultment: define as absence from scheduled therapy or follow up more than 4 
weeks. 
Overall survival: from the date of diagnosis till patients death/ last contact/ date of 
census. 
Event free survival: is time from diagnosis to the date of any event, date when patients 
confirm to be well/cure, or to the date of any major complications. 
Median survival: is the time when half of children are expected to be alive (the chance 
of surviving beyond that time is 50%) 
Relapsed: any disease recur 
Major Complications: Includes severe sepsis, Neurological complications, Cardiology 
complications, Coagulations and bleeding, Complication treatments (DVT, liver 
toxicity) secondary malignancies. The complication excluded death as death was 
considered the outcomes. 
Events: Were considered as well/cure, defaultation, death, major complications, date of 
census. 
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CHAPTER FOUR 
 
RESULTS 
 
Total number of 51 children who were suspected with Ewing Family Tumor (EFT) at 
presentation, were seen in Paediatric Oncology ward and Orthopaedic Ward from 1st 
January 2002 to 31st December 2012. These data were obtained from the registration 
record office. The patients involved only included paediatric patients aged 0- 18 years 
of age.  
Out of 51 patients, only 29 patients were enrolled in the study. This is because 15 of 
them were diagnosed of other diagnosis based on biopsy and HPE (Histopathology 
examination). The diagnosis include Chronic Osteomyelitis (n=6), Osteosarcoma (n=5) 
and Langerhans Cell Histiocytosis (n=1). Two patients have normal HPE result and one 
patient with uncertain diagnosis due to missed follow up.  
Thirty one patients with confirmed EFT but two of them need to be excluded because 
one of them was started chemotherapy at other hospital and used different 
chemotherapy regime than our hospital. The other one was diagnosed earlier than our 
study period (2000). Five folders were missing. 
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4.1 Demographic Profile of Children with Ewing Family Tumor 
 
Table 1: Demographic profile of children with Ewing Family Tumor (EFT).(n=29) 
__________________________________________________________________ 
Features      n   %  
               
 
Gender 
 Male      16   55.2  
 Female     13   44.8 
 
Age 
 <10 years     6   20.7 
 ≥10 -18 years     23   79.3 
 
Race  
 Malay      25   86.2 
 Chinese     1   3.4 
 Indian      3   10.3 
 
 
Parental Education  
 Primary     7   24.1 
 Secondary     7   24.1 
 Tertiary     5   17.2 
 Missing data     10   34.5 
 
______________________________________________________________________ 
 
 
Table 1 above showed demographic profile of children with Ewing Family Tumor in 
HUSM from 2002-2012. Out of 29 subjects, the minimum age was 4.6 years and the 
maximum age was 17.7 years. Mean age was 12.0 years old (SD: 3.74). Majority of 
patients were 10 years and above (79.3%).  
Most of patients were predominantly male (55.2%) compare to female (44.8%). The 
incidence in male was 1.3 times higher compared to female. Majority were Malays 
(86.2%). Whereby, others were from Indian (10.3%) and Chinese (3.4%).  
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In terms of academic background of parent, one third of data was missing, (n=10, 36.7 
%) as no documentation of the parental education in the folder. Otherwise it was nearly 
well distributed among primary (24.1%), secondary (24.1%) and tertiary (17.2%) level 
of education. 
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4.2 Patients Characteristic of Ewing Family Tumor  
Table 2: Patients Characteristic of Ewing Family Tumor (n=29) 
______________________________________________________________________ 
Characteristic     n   %  
  
______________________________________________________________________ 
 
Primary Tumor site 
 Extremities    16   55.2 
 Pelvis     8   27.6 
 Axial     5   17.2 
 
Disease Profile  
 Classical Ewing Sarcoma  11   37.9 
 PNET     16   55.2 
 Extraosseous    2   6.9 
  
Symptoms 
 Pain     2   6.9 
 Palpable mass    8   27.6 
 Pain and mass    10   34.5 
 Paraplegia    8   27.6 
 Paraesthesia/redness   1   3.4 
 
Size of tumor 
 <8cm     3   10.3 
 ≥8cm     21   72.4 
 Missing data    5   17.2 
 
Metastasis at diagnosis 
 Yes     11   37.9   
 No      15   51.7 
 Missing data    3   10.3 
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______________________________________________________________________ 
 Characteristic     n   %  
  
______________________________________________________________________ 
 
Lung metastasis at diagnosis       
 Yes     11   37.9 
 No      15   51.7 
 Missing data    3   1 
 
Skip bone metastasis at diagnosis 
 Yes     3   10.3 
 No      16   55.2 
 Missing data    10   34.5  
  
 
Surgical intervention 
 Surgery     13   44.8  
  
 No surgery    16   55.2 
 
Chemotherapy protocol 
 Ewing Euro 99   8   27.6 
 PNET1     3   10.3 
 CAV/IE2    14   48.3 
 MSK3      2   6.9 
 Unknown    1   3.9 
 
Complications 
 Sepsis      8   27.6 
 Neurology complication  3   10.3 
 Others4    3   10.3 
 Nil      15   51.7 
 
 
